NEW YORK (GenomeWeb News) – Nimbus Discovery today announced an extension of its seed round of funding, which will be used to advance drug programs based on its in silco discovery platform.
The funding comes from Bill Gates and Richard Freisner, co-founder of chemical simulation software firm Schrödinger and a professor of chemistry at Columbia University. Atlas Venture, the founding investor in Nimbus, also was a participant.
Nimbus did not disclose the amount of the investment.